CIM
GILD icon

Cambria Investment Management’s Gilead Sciences GILD Stock Holding History

Cambria Investment Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$960K Buy
7,599
+3,016
+66% +$397K 0.05% 335
2026
Q1 		$639K Buy
+4,583
New +$642K 0.04% 358

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cambria Investment Management's GILD Position: Q2 2026 in Review

Cambria Investment Management increased its Gilead Sciences (GILD) stake by 66% in Q2 2026, buying an estimated $397K and bringing the position to 7,599 shares worth $960K. The position accounts for 0.05% of the portfolio, ranked #335.

Cambria Investment Management first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Cambria Investment Management held 7,599 shares of Gilead Sciences worth $960K as of Q2 2026.
  • Cambria Investment Management bought 3,016 Gilead Sciences shares in Q2 2026, an estimated $397K.
  • Gilead Sciences made up 0.05% of Cambria Investment Management's portfolio in Q2 2026, its #335 holding.
  • Cambria Investment Management first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Cambria Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.